Effects of Dry Needling on Function, Muscle Tone and Quality of Life in Parkinson’s Disease

Overview

Hypothesis: Dry needling in lower limbs produces a change in function (assessed by the 6 minute walk test, timed up and go, 10 meter walk test and unified scale for Parkinson's disease) and muscle tone (assessed by tonometry and the modified of Modified Ashworth scale(MMAS)) in patients with Parkinson's disease. The main objective of this study is to analyze the effect of dry needling on function and muscle tone in subjects with Parkinson disease. The secondary objective is to analyze the longterm effects of dry needling on function and muscle tone in subjects with Parkinson disease.

Full Title of Study: “Effects of Dry Needling on Function, Muscle Tone and Quality of Life in Parkinson’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: December 5, 2019

Detailed Description

Methods: It is a double-blinded randomized clinical trial where subjects are patients from Zaragoza and have been diagnosed with Parkinson´disease by a neurologist. Inclusion criteria: – Patients diagnosed with Parkinson by a neurologist. – Age: 50 – 90 years. – Presence of Hypertonia according to: MMAS score > 1 during movement of ankle dorsiflexion or knee flexion and extension. Exclusion criteria: – Degenerative diseases that may affect the results. – Presence of fixed contractures. – Fear of needles. – No tolerance to pain caused by dry needling – No commitment to continuity. – Attrition criteria Attrition criteria: – Adverse effects relate to the DNHS technique. – Subject Uncooperative that prevents proper protocol execution performance -Voluntary decision of the patient. Intervention: There will be an intervention group (dry needling into the muscles of the lower limbs that present tone dysfunction according to an expert clinician) and a control group (sham dry needling). The intervention will be a unique session. Dry needling technique will be performed by locating the taut band and the Myofascial Trigger Point by an expert clinician. After that, a thin needle (0,32x40mm) is introduced directly into a Myofascial Trigger Point with the aims to generate a "local twitch response" that are involuntary contractions of the muscle fibers. This puncture may reproduce patient's symptoms, and causes muscle relaxation to achieve at the same time the relief of muscle tension and pain and also to recover the metabolism of the muscle. Assessment: Outcome measures will include tone muscle measured by tonometry and the MMAS and functional clinical scales including: 6 minute walk test, timed up and go, 10 meter walk test and Unified Parkinson's Disease Rating Scale.

Interventions

  • Other: Dry needling
    • Dry needling into spastic muscle
  • Other: Sham dry Needling
    • Sham dry needling into spastic muscle

Arms, Groups and Cohorts

  • Experimental: Dry needling
    • One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is >1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
  • Sham Comparator: Sham Dry needling
    • A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.

Clinical Trial Outcome Measures

Primary Measures

  • 6 minute walk test
    • Time Frame: Change between baseline (immediately before intervention) and post intervention (immediately after intervention). Change between baseline (immediately before intervention) and follow-up (at 1 week after intervention)
    • It measures the maximum distance that the subject is able to travel in 6 minutes. It allows to obtain the speed of walking.
  • Timed up and go test
    • Time Frame: Change between baseline (immediately before intervention) and post intervention (immediately after intervention). Change between baseline (immediately before intervention) and follow-up (at 1 week after intervention)
    • It measures patient mobility. The patient should get up from a chair with armrests, walk three meters, turn on himself, step back three meters and sit back down. If the patient takes less than 10s, it is considered normal mobility and more than 20s reduced mobility
  • 10 meter walk test
    • Time Frame: Change between baseline (immediately before intervention) and post intervention (immediately after intervention). Change between baseline (immediately before intervention) and follow-up (at 1 week after intervention)
    • It used to assess walking speed in meters/second (m/s) over a short distance

Secondary Measures

  • Modified Modified Ashworth score
    • Time Frame: Change between baseline (immediately before intervention) and post intervention (immediately after intervention). Change between baseline (immediately before intervention) and follow-up (at 1 week after intervention)
    • Scale measuring Spasticity/Hypertonia. This scale ranges from 0 to 4 points for each muscle assessed, where 0 is no hypertonia/spasticity and 4 is the highest hypertonia/spasticity.
  • Tonometry (measurement of muscle tone with a device)
    • Time Frame: Change between baseline (immediately before intervention) and post intervention (immediately after intervention). Change between baseline (immediately before intervention) and follow-up (at 1 week after intervention)
    • Muscle stiffness or muscle tone (Quadriceps, Hamstring, soleus and gastrocnemius). This device register different parameters like frequency, oscillation, etc that are related to tone, and start from 0 to an undefined number (depending on every muscle). It is a quantitative measurement. It is a quantitative measurement.
  • Unified Parkinson’s Disease Rating Scale
    • Time Frame: Change between baseline (immediately before intervention) and follow-up at 1 week after intervention
    • It measures the motor and cognitive function, the activities of daily life, as well as the possible complications that can alter the patient’s life. The score ranges from 0 to 199, where 199 represents total disability and 0 no disability

Participating in This Clinical Trial

Inclusion Criteria

  • Patients diagnosed with Parkinson by a neurologist – Age: 50 – 90 years – Presence of Hypertonia according to: MMAS score > 1 during movement of ankle dorsiflexion or knee flexion and extension Exclusion Criteria:

  • Degenerative diseases that may affect the results. – Presence of fixed contractures. – Fear of needles – No tolerance to pain caused by dry needling – No commitment to continuity

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universidad San Jorge
  • Collaborator
    • University of Castilla-La Mancha
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Elisabeth Bravo, Phd, Study Director, University of Castilla-La Mancha

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.